Personalized, Precise Treatments for Depression and Bipolar Illness

John F. Greden, M.D.

Introduction

Dr. John Greden is the Founder and Executive Director of the University of Michigan Comprehensive Depression Center in Ann Arbor, Michigan. He also is the Rachel Upjohn Professor of Psychiatry and Clinical Neurosciences in the Department of Psychiatry, a Research Professor in the Molecular and Behavioral Neuroscience Institute, Past-President of various research societies including the American Foundation for Suicide Prevention, and past Chair of Psychiatry at Michigan.

Dr. Greden has been at Michigan for more than three decades. He served as Department Chair from 1985 to 2007, and in 2001, proposed establishment of the University of Michigan Depression Center, the inaugural Center of its kind. Because he also is passionate about working collaboratively, Dr. Greden led the founding of the National Network of Depression Centers (www.NNDC.org). The NNDC is a collaborative network of 25 Centers of Excellence throughout the United States, comparable to the National Network of Cancer Centers. By sharing and bringing experts together, the NNDC is integrating stronger voices to overcome stigma, conducting research to develop new and safer treatments and preventive strategies, and organizing global education efforts.

During Dr. Greden’s career, he has focused on the role of stress in depressions, bipolar illnesses (sometimes called manic-depression), and anxieties, on their lifetime course, and on strategies for maintaining wellness. He has more than 300 scientific publications and books and has given more than 400 invited lectures. Knowing that these illnesses have their peak ages of onset during teenage years he has been a strong advocate of the need to think about detection, treatment and prevention in our youthful populations. He was recently awarded a prestigious honor by the Governor of Michigan for his outstanding work and contribution to the field of Psychiatry.

Learning Objectives

• Explain why clinical depressions and bipolar illnesses lead the world in health burdens and costs.
• Recognize that mood disorders have common phenotypes (clinical features), but these may develop from different underlying causes, thus explaining why "one size treatment will never fit all."
• List available approaches to best determining personalized, precise treatments ("the right treatment for the right person at the right time").
• Explain why co-occurring diseases such as cardiovascular illnesses, diabetes, cancers and other chronic illnesses may have higher risks for depressions and bipolar illnesses and descirbe possible future treatment implications.

Live webcast available at:  http://videos.mayo.edu/live

1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live.  MedHub will be implemented for all post presentation surveys.  Your name and e-mail are not linked to your evaluation. Identifiers are tracked separately for attendance records only.  To document your attendance, please send an email to rstpsychgr@mayo.edu. The badge reader should continue to be utilized for Gonda and Sister Helen Hayes locations.

Credit Statements

·         Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

·         Mayo Clinic College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

Disclosure Summary

As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development), must ensure balance, independence, objectivity and scientific rigor in its educational activities.   Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry: 

Speaker:  John F. Greden, M.D.

Consultant:  Janssen, Naurex (Allergan), Cerecor, Assurex (unpaid), NeuralStem

Honoraria:  Various invited lectures

Other:  Royalities from book sales

No relevant financial relationship(s) with industry:

Brian Palmer, M.D., Michael Bostwick, M.D., Karen Grothe, Ph.D., Lois Krahn, M.D., Jarrod Leffler, Ph.D., Larissa Loukianova, M.D., Mary Machulda, Ph.D., Patricia Maus, M.D., Amber Pearson, Jeffrey Staab, M.D., Cosima Swintak, M.D., Kristin Vickers Douglas, Ph.D., Cynthia Harbeck-Weber, Ph.D., Michael Zaccariello, Ph.D., Georgina Rink, Charlene Nelson

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

John F. Greden, M.D.:  Will likely refer to Ketamine as a treatment option

Questions regarding this program can be directed to rstpsychgr@mayo.edu.